Polatuzumab (32, 33), an antibody drug conjugates(ADC) antibody drug targeting CD79B, binds to the CD20 antigen, inhibiting B cell growth and proliferation in the CD79B region, and has been proven to have therapeutic effects in specific types of lymphomas, such as DLBCL and EMZL refractory or relapsed cases. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.